The incidence of tuberculosis (TB) in Canada has been declining. According to Health Canada, in 2012 the national incidence was 4.8 per 100 000, and in British Columbia 6.1 per 100 000. In certain groups, including Aboriginal communities, newly arrived immigrants from high-endemicity countries, and indigents, the incidence of TB is higher than the population average.
In Canada the risk of occupationally acquired TB is low. Nevertheless, people who work with high-risk groups may occasionally be exposed to infectious individuals. When that happens, the affected worker will require a thorough assessment to determine if he or she has been infected and, if so, that worker should receive treatment.
If your patient suspects that he or she has been exposed to TB at work, encourage him or her to file a claim with WorkSafeBC. You can assist in the claim process by providing relevant clinical information in a timely manner. If medically appropriate, you may also refer the individual to the BC Centre for Disease Control TB clinic for expert assessment and management.
To adjudicate a TB claim, WorkSafeBC requires the following (in addition to basic demographic information):
• The claimant’s history of TB exposure, testing, infection status, and treatment
• BCG vaccination status and time of administration
• Place of birth and immigration history
• Recent travel history
• Work history, including work in high-risk countries and communities, and with high-risk groups
• Detailed information about the exposure, including the work circumstances, duration of exposure, and reliable confirmation of exposure to an infectious individual with active TB. An infectious individual is one who is actively coughing, has a confirmed medical diagnosis typically based on positive smear for AFB, or positive cultures and corresponding radiological evidence.
• TB testing results
• Chest X-ray results
• Other test results such as sputum cultures or smears
In cases of active TB disease, treatment should be started based on culture result and recommendations of an infectious disease specialist. For suspected latent TB infections, confirmatory TB testing, including the Mantoux or 5 TU PPD TB skin test (TST) or an interferon gamma release assay (IGRA), is required.
The timing of these tests is important. Tests done within days of the exposure relate to prior infection status, because the cell mediated immune reaction on which the TB tests are based takes time to develop. Tests related to the recent exposure need to be done at least 4 to 8 weeks after the incident. However, doing both tests can be useful. If the early TST is negative and the second delayed TST is positive, this would be strong evidence that the TB conversion is new and likely related to the recent exposure. Of course, these results could also represent a booster phenomenon. However, unless there’s additional compelling clinical evidence of this, the conversion is usually attributed to the recent exposure.
Confirmed cases of new latent TB infections typically require prophylactic treatment with a recommended regimen such as INH for 9 months.
For more information
If you have a query or need more information regarding a TB claim, contact Peggy Tunks, client services manager in WorkSafeBC’s Occupational Disease Services, at 604 231-8842. Or contact your patient’s claim manager or a medical advisor in the nearest WorkSafeBC office.
—Sami Youakim, MD, MSC, FRCP
WorkSafeBC Occupational Disease Services
BC Centre for Disease Control. Annual summaries of reportable diseases. Accessed 20 January 2016. www.bccdc.ca/health-professionals/data-reports/annual-summaries-of-reportable-diseases.
Public Health Agency of Canada. Canadian tuberculosis standards, 7th edition. Accessed 20 January 2016. www.phac-aspc.gc.ca/tbpc-latb/pubs/tb-canada-7/index-eng.php.
This article is the opinion of WorkSafeBC and has not been peer reviewed by the BCMJ Editorial Board.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org